间歇性禁食联合苓桂术甘汤和益生元对非酒精性脂肪肝小鼠的 作用研究.

Objective: To investigate the therapeutic effects and mechanisms of intermittent fasting combined with Lingguizhugan decoction and prebiotics on non-alcoholic fatty liver disease (NAFLD). Methods: NAFLD mouse models were established using a 12-week high-fat diet (HFD). The intervention groups were: intermittent fasting (IF), IF combined with low-dose Lingguizhugan decoction (IFLGL), IF combined with high-dose Lingguizhugan decoction (IFLGH), IF combined with prebiotics (IFpre), and IF combined with prebiotics and high-dose Lingguizhugan decoction (IFLGpre). Body weight, serum biochemical indices, liver histology, gut microbiota composition, and expression of genes related to the SREBP-1 pathway were measured in each group as parameters. Results: Compared to the model group, all intervention groups showed significant reductions in body weight and serum biochemical indices, including ALT, AST, cholesterol (CHO), triglycerides (TG), HDL-C, and LDL-C (P<0.01). Hepatic lipid accumulation and histopathological damage were notably alleviated in all intervention groups. Compared to the control group, the model group had significantly lower gut microbiota a-diversity indices (ACE, Chaol, Simpson) (P<0.05). However, these indices were increased significantly after intervention in the IF, IFLGH, IFpre, and IFLGpre groups (P<0.01). Additionally, these four interventions significantly enhanced the abundance of beneficial bacteria such as Lactobacillale and Bifidobacteriale. The IFLGpre group demonstrated the most significant improvements in body weight, liver function indices (ALT, AST), lipid profiles (TG, CHO, HDL-C), liver histology, and gut microbiota composition, with statistically significant differences compared to other intervention groups. All interventions significantly downregulated SREBP-1c and FAS gene expression in the liver (P<0.01), reducing hepatic lipid accumulation. Conclusion: Intermittent fasting combined with Lingguizhugan decoction and prebiotics ameliorates NAFLD by modulating gut microbiota and the SREBP-1 pathway. Combined interventions have superior therapeutic effects. [ABSTRACT FROM AUTHOR]